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The Genetic Aspects of Behçet’s 
Disease: Role of Cytokine Genes 
Polymorphisms
Abdulrahman Al Asmari and Misbahul Arfin
Abstract
Behçet’s disease (BD) is a complex, multisystemic inflammatory disorder 
characterized by recurrent oral aphthous ulcers, ocular symptoms, skin lesions, 
and genital ulcerations. The etiology of BD is not yet clear though various factors 
including environmental, genetic and immunological ones have been implicated. 
Genetic predisposition is a major factor in disease susceptibility and multiple host 
genetic factors have been suggested to be involved in the development of BD. In 
addition to the positive association of HLAB*51, recent studies report additional 
independent associations in the non HLA loci. Single nucleotide polymorphisms 
(SNPs) in various genes including cytokines have been implicated in susceptibil-
ity to BD. However, the results are inconsistent and variation are found in several 
ethnic populations. Therefore, further genetic studies on BD patients of different 
ethnicity and genes associated with immunity are expected to elucidate BD patho-
genesis and will contribute to the development of more targeted therapies and 
biomarkers.
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1. Introduction
Behçet’s disease (BD; MIM 109650) is a multisystemic inflammatory disorder 
characterized by recurrent oral aphthous ulcers, ocular symptoms, skin lesions, and 
genital ulcerations. BD has many features in common with systemic vasculitis. The 
prevalence of BD varies, it is more prevalent in the Far East, the Mediterranean and 
the Middle Eastern countries along the ancient Silk Road [1–3]. The highest preva-
lence has been reported in Turkey (80–420 cases per 100,000) followed by Israel 
(146.4), China (110), Iran (80), Korea (30.2), Japan (22), Saudi Arabia (20), Iraq 
(17), Morocco (15), and Egypt (7.5) cases per 100,000 [1, 3, 4].
Clinical and immunological understandings of the disease suggest that BD is a 
cornerstone between autoimmune and inflammatory disease [5]. Due to effective-
ness of immunosuppressives [6] and involvement of human heat-shock protein 60 
(HSP60) [7], it is considered as an autoimmune disease. While on the basis of lack 
of antigen-specific T-cells or significant high-titer auto-antibodies, insignificant 
involvement of histocompatibility complex (MHC) class I molecules together with 
unprovoked recurrent inflammation episodes mainly caused by neutrophils [8], the 
association of the M694V MEFV mutation with its susceptibility and the therapeutic 
effectiveness of colchicine, BD is classified as an auto-inflammatory disease [4].
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Although it is thought that common environmental factors such as infections or 
exposures to toxins or to specific immunogens contribute to BD, development of 
disease is believed to occur only in genetically predisposed hosts. BD is a complex 
disease and different patients experience different symptoms. The etiology of BD 
is very complex and it is thought that environmental factors, genetic predisposition 
and immune dysregulation are involved in the pathogenesis of BD [9–14]. The wide 
range of disease prevalence observed among different geographic locales is likely 
a result of differences in both environment and genetics. The aim of this study is 
to highlight the genetic aspect of BD with emphasis on the role of cytokine genes 
polymorphisms in the susceptibility/etiopathogenesis of BD.
2. Genetic aspect of Behçet’s disease
Genetic predisposition is a major factor in disease susceptibility and multiple 
host genetic factors have been suggested to be involved in the development of 
BD. The association of HLAB*51 with BD susceptibility has been confirmed in sev-
eral populations since it was discovered more than four decades ago however, recent 
studies indicate association in the major histocompatibility complex class I region 
and several non HLA loci also. Class I alleles, HLA-A*26, -B*15, -B*27, and -B*57, 
have been reported as independent risk factors for Behçet’s disease while HLA- A*03 
and -B*49 are protective for it [15].
The candidate gene approach has been useful in identifying susceptibility and 
severity genes in BD. Single nucleotide polymorphisms (SNPs) in various genes (IL-
10, TNF-α, TNF-β, STAT4, IL23R, CD40, CCR1/CCR3, STAT3, MCP-1, TGFBR3, 
FCRL3, SUMO4, UBAC2) have been implicated in susceptibility to BD. However, 
the results are inconsistent and variation are found in several ethnic populations. 
Genome-wide association studies have also identified associations with IL23R–
IL12RB2, IL10, STAT4, CCR1-CCR3, KLRC4, ERAP1, TNFAIP3, and FUT2 loci [15]. 
Moreover rare mutations in IL23R, TLR4, NOD2, and MEFVr genes have been found 
to be linked with BD pathogenesis by targeted next-generation sequencing.
The variations in the mRNA expression/gene function indicate the role of the 
risk alleles in the pathogenesis of disease. Several susceptibility genes, which may 
regulate the immune reaction, have been found to be associated with BD. However, 
the precise mechanism of these genes in the development of BD is currently 
unknown [10, 11, 16]. The genes identified are involved in both innate and adap-
tive immunity and support the idea that polarization in Th1/Th17 pathway plays a 
critical role in BD pathogenesis. Commonalities of susceptibility genes with other 
immune-related diseases/inflammatory disorders shows shared features of immune 
related diseases with BD. The interaction between genetic factors and environmen-
tal factors has also been suggested in several recent studies.
Cytokines are believed to mediate inflammation in BD [17, 18]. Various studies 
have found increased levels of tumor necrosis factor (TNF)-α and decreased levels 
of interleukin (IL)-10 in the serum and active lesions of BD patients and suggested 
that these cytokines play a significant role in the immune response, pathogenesis 
and activity in BD [12, 19–24].
Cytokines play critical roles in the pathogenesis of BD, since they mediate many 
of the effector and regulatory functions of immune and inflammatory responses 
[14, 17]. Genetic polymorphisms in several cytokine genes have been described and 
demonstrated to influence gene transcription, leading to inter individual variations 
in cytokine production. It has been suggested that genetic polymorphisms that 
regulate the production of certain cytokines are important determinants of suscep-
tibility to BD and its some of the clinical and laboratory features [14, 25, 26]. BD has 
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been considered to be a typical Th1-mediated inflammatory disease, characterized 
by elevated levels of Th1 cytokines such as IFN-γ, IL-2, and TNF-α. Recently it 
has been reported that Th1- and Th17-related cytokines and signaling molecules 
participated in BD pathogenesis [27, 28].
A number of studies reported that the levels of T helper Type 1 cytokines are 
increased in sera of the patients with BD. Some studies have shown that the maxi-
mal capacity of cytokine production varies among individuals and correlate with 
single nucleotide polymorphism in various cytokine genes [29–32]. However the 
results of the association of cytokines genes polymorphism with susceptibility and 
pathogenesis of BD are inconsistent and further studies involving different ethnic 
populations have been suggested [14].
3. Tumor necrosis factor (TNF)-α polymorphisms
Besides HLA-B51 molecules, SNPs in TNF genes have been implicated in sus-
ceptibility to BD [14, 33–37]. TNF-α is a pro-inflammatory cytokine and involved 
in regulation of the immune response. It is encoded in the Class III region of the 
HLA complex adjacent to HLA-B. TNF-α mediates the activation of macrophages 
and apoptosis and it is involved in recurrent inflammatory episodes in BD patients 
[23, 38]. Many studies have suggested it as both positional and functional candidate 
gene in the onset and progression of BD [14, 33–35, 39].
Promoter polymorphism of TNF-α (−308G/A) and intronic polymorphism 
TNF-β (252A/G) have been associated with variations in the level of circulating 
TNF-α [40]. TNF-α (−308G/A) polymorphism (rs1800629) results into a less com-
mon allele-A (allele 2) which leads to increased TNF-α production in vitro [41] and 
higher rate of TNF-α transcription than wild type allele-G (allele 1). Allele-A pro-
duces 6–7 fold higher levels of TNF-α transcription [42–44]. TNF-α production and 
expression is regulated by single nucleotide polymorphisms (SNPs) in TNF-α gene 
[25, 42]. Several SNPs in TNF-α gene have been associated BD in different ethnic 
groups [14, 36, 45–47]. The outcome of various studies on association between BD 
and SNPs of TNF-α in different ethnic groups are summarized in Tables 1–6.
3.1 TNF-α (−308 G/A) polymorphism
A number of studies has determined the relationship between the -308A/G 
polymorphism and BD with inconsistent results (Table 1). The genotype GA and 
allele-A are associated with susceptibility of BD in Saudis [14] while genotype GG 
and allele G are associated with its susceptibility in Korean patients [33]. On the 
other hand no association is found in Caucasoid [39], Iranian [48], Iranian (Azeri 
Turkish) [54], Korean [49, 50] Lebanese [51], Tunisian [46], Turkish [38, 45, 52, 53] 
and Moroccan [47].
Two independent meta-analysis have revealed an association between −308A and 
BD risk in the overall [34, 35] however, stratification by ethnicity indicates that the 
−308A allele is significantly associated with BD risk in the Asian population [35].
3.2 TNF-α (−238 A/G) polymorphism
The TNF-238A/G polymorphism has been studied in BD patients from different 
ethical populations and several reports are available on the association between the 
TNF−238A/G polymorphism and BD risk with contrast results. Genotype AA is 
found to be associated with BD in Turkish population [55] whereas genotype GG 
is associated with BD in Iranian patients [48]. Other individual studies on German 
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[56], Iranian (Azeri Turkish) [57], Korean [33, 50], Lebanese [51], Moroccan [47] 
and Turkish [38, 56] BD patients show no association of TNF−238A/G polymor-
phism with susceptibility of BD (Table 2). However two meta-analysis indicates 
that allele-A is associated with BD susceptibility [35, 36]. In the subgroup analysis 
by ethnicity, Zhang et al. [35] suggests that the BD cases has a significant higher 
frequency of A in the Caucasian than that in the controls.
3.3 TNF-α (−1031 C/T) polymorphism
There is a strong evidence indicating the role of TNF-α (−1031 C/T) 
Polymorphism with BD susceptibility. A number of studies examined the association 
of TNF-α −1031C/T with BD in different populations. Results indicate, a significant 
association between the TNF-α −1031C/T polymorphism and BD susceptibility in 
Population Case/controls Genotype/allele/polymorphism Association Reference
Saudi 61/211 GA/A Susceptible [14]
Korean 254/344 GG/G Susceptible [33]
Korean 94/94 GA polymorphism No 
association
[49]
Korean 115/114 GA polymorphism No 
association
[50]
Turkish 99/96 GA polymorphism No 
association
[52]
Turkish 107/102 GA polymorphism No 
association
[38]
Turkish 97/127 GA polymorphism No 
association
[53]
Turkish 102/102 GA polymorphism No 
association
[45]
Lebanese 48/90 GA polymorphism No 
association
[51]
Iranian 147/137 GA polymorphism No 
association
[48]
Iranian 
(Azeri 
Turkish)
53/79 GA polymorphism No 
association
[54]
Moroccan 120/112 GA polymorphism No 
association
[47]
Tunisian 89/157 GA polymorphism No 
association
[46]
Caucasoid 133/354 GA polymorphism No 
association
[39]
Meta-
analysis
− GA polymorphism No 
association
[36]
Meta-
analysis
1372/1754 GA polymorphism Susceptible [34]
Asian* 1232/1397 A-allele Susceptible [35]
*Meta-analysis.
Table 1. 
Association of TNF-α-308 polymorphism with BD susceptibility.
5The Genetic Aspects of Behçet’s Disease: Role of Cytokine Genes Polymorphisms
DOI: http://dx.doi.org/10.5772/intechopen.88856
Turkish [29, 58], Iranian (Azeri Turkish) [54], Korean [33], and Tunisian patients 
[46] (Table 3). Touma et al. [36] in a meta-analysis, identified a significant associa-
tions between the −1031C/T polymorphisms and BD risk. Stratifying by ethnicity, 
in another meta-analysis a significant association in the Caucasian population is 
noticed [35]. Radouane et al. [47] suggested that TNF-1031C constitutes a suscepti-
bility allele for BD in Moroccan, especially with genital ulcers.
In contrast, Chang et al. [50] discovered no significant difference in the 
allele frequency of TNF-α −1031C/T between patients with BD and controls in a 
Korean population. There was no significant association of this polymorphism in 
Lebanese BD patients also [51]. Moreover the analysis of the influences this poly-
morphism on various clinical manifestations of BD showed that TNF-α −1031C is 
not related to the presence of clinical features, such as oral and genital ulceration 
and uveitis.
3.4 TNF-α (−857 T/C) polymorphism
A number of studies has been focused on the association between the TNF-α-
857T/C polymorphism and BD risk [Table 4]. Two independent studies indicate 
an association of TNF-α-857T/C polymorphism with BD susceptibility in Korean 
and Iranian (Azeri Turkish) Cohort [33, 57]. Other studies performed on Korean, 
Lebanese, and Moroccan BD patients show no significant association of this poly-
morphism and BD susceptibility [47, 50, 51]. However a meta-analysis suggested 
that T-allele of TNF-α-857T/C polymorphism is associated with BD susceptibility 
[36]. Later on another meta-analysis also indicated that this association is a signifi-
cant risk factor in Asian population [35].
Population Case/controls Genotype/allele/polymorphism Association Reference
Turkish 107/102 A/G polymorphism No 
association
[38]
Turkish 80/105 AA Susceptible [55]
Turkish 30/20 A/G polymorphism No 
association
[56]
Korean 254/344 A/G polymorphism No 
association
[33]
Korean 115/114 A/G polymorphism No 
association
[50]
German 92/51 A/G polymorphism No 
association
[56]
Lebanese 48/90 A/G polymorphism No 
association
[51]
Moroccan 120/112 A/G polymorphism No 
association
[47]
Iranian 150/140 GG Susceptible [48]
Iranian (Azeri 
Turkish)
64/101 A/G polymorphism No 
association
[57]
Meta-analysis − A-allele Susceptible [36]
Caucasian* 842/938 A-allele Susceptible [35]
*Meta-analysis.
Table 2. 
Association of TNF-α –238 polymorphism with BD susceptibility.
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3.5 TNF-α (−863 A/C) polymorphism
TNF-863A/C polymorphisms has been studied in Korean, Moroccan and 
Lebanese BD patients. Results of these studies indicated that there is no significant 
association of polymorphism with BD susceptibility (Table 5) [47, 50, 51] though 
one study suggested an association in Korean patients [33]. However two indepen-
dent meta-analysis also did not find any significant role of this polymorphism in BD 
susceptibility [35, 36].
3.6 TNF-α (−376 A/G) polymorphism
Three reports are available on −376A/G polymorphism in BD, two studies were 
performed in Turkish while the third one in Moroccan patients. These studies identi-
fied no significant association with BD risk (Table 6). The results of the meta-analysis 
Population Case/controls Genotype/allele/polymorphism Association Reference
Turkish 99/103 C/T polymorphism Susceptible [29]
Turkish 82/77 CC Susceptible [58]
Iranian (Azeri 
Turkish)
53/79 C-allele Susceptible [54]
Korean 254/344 C/T polymorphism Susceptible [33]
Korean 115/114 C/T polymorphism No association [50]
Tunisian 89/157 C-allele Susceptible [46]
Lebanese 48/90 C/T polymorphism No association [51]
Caucasoid (UK) 133/354 C/T polymorphism Susceptible [39]
Moroccan 120/112 C-allele Susceptible [47]
Meta-analysis C- allele Susceptible [36]
Caucasian* 738/964 C- allele Susceptible [35]
*Meta-analysis.
Table 3. 
Association of TNF-α –1031 polymorphism with BD susceptibility.
Population Case/controls Genotype/allele/polymorphism Association Reference
Korean 254/344 C-allele Susceptible [33]
Korean 115/114 T/C polymorphism No 
association
[50]
Lebanese 48/90 T/C polymorphism No 
association
[51]
Moroccan 120/112 T/C polymorphism No 
association
[47]
Iranian (Azeri 
Turkish)
64/101 C-allele Susceptible [57]
Meta-analysis T-allele Susceptible [36]
Asian* 533/660 T/-allele Susceptible [35]
*Meta-analysis.
Table 4. 
Association of TNF-α –857 polymorphism and BD in various populations.
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by Zhang et al. [35] also showed that the TNF-376A/G polymorphism is not associated 
with BD susceptibility and this polymorphism does not appear to have a significant 
association with overall BD risk.
4. TNF-β (–252A/G) polymorphism
TNF-β has been reported to contribute to the susceptibility of some inflamma-
tory and autoimmune diseases [58–62]. Gamma delta T cells of BD patients produce 
higher levels of TNF-β than those of healthy controls [63, 64]. A polymorphism in 
the intron 1 of TNF-β has been associated with higher TNF-α and TNF-β produc-
tion. TNF-β (+252A/G) polymorphism (rs909253) contains a Guanine (G) on one 
allele and an adenine (A) on the alternate allele. TNF-β +252G allele is defined as 
mutant allele and known as TNF-β*1 (allele-1). This mutant allele-1 is associated 
with increased levels of TNF-α and TNF-β [65, 66].
To the best of our knowledge five studies have been focused on TNF-β 
(+252A/G) polymorphism and BD (Table 7). The results of three studies in Saudi, 
Korean and Tunisian BD patients indicated that TNF-β (+252A/G) polymorphism 
has no significant association with BD susceptibility. However one report from 
Population Case/controls Genotype/allele/polymorphism Association Reference
Korean 254/344 A/C polymorphism Susceptible [33]
Korean 115/114 A/C polymorphism No association [50]
Moroccan 120/112 A/C polymorphism No association [47]
Lebanese 48/90 A/C polymorphism No association [51]
Meta-analysis − A/C polymorphism No association [36]
Asian* 486/560 A/C polymorphism No association [35]
*Meta-analysis.
Table 5. 
Association of TNF-α–863 polymorphism with BD in various populations.
Population Case/controls Genotype/allele/polymorphism Association Reference
Turkish 99/96 A/G polymorphism No association [52]
Turkish 107/102 A/G polymorphism No association [38]
Moroccan 120/112 A/G polymorphism No association [47]
Table 6. 
Association of TNF-α–376 polymorphism with BD susceptibility.
Population Case/controls Genotype/allele/polymorphism Association Reference
Saudi 61/211 AG polymorphism No association [14]
Tunisian 89/157 AG polymorphism No association [46]
Korean 94/94 AG polymorphism No association [49]
Middle eastern 102/115 A-allele Susceptible [67]
Japanese 79/75 A-allele Susceptible [68]
Table 7. 
Association of TNF-β–252 polymorphism with BD susceptibility.
Cytokines
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Palestinian and Jordanian populations indicates that the frequency TNF-β +252 A 
allele (allele-2) is increased in BD cases compared to controls [67]. On the basis 
of strong linkage disequilibrium found between HLA-B*51 and allele-A of TNF-β 
(+252A/G) polymorphism it has also been suggested that that both the alleles con-
tribute to BD risk and their co-expression may cause severe eye pathogenicity lead-
ing to blindness [67]. Another report by Mizuki et al. [68] shows that the frequency 
of homozygous genotype (GG) of TNF-β (+252A/G) is significantly decreased in 
Japanese ocular BD patients than controls.
5. Interleukin (IL) gene polymorphisms
Interleukins are cytokines that mediate communication between cells. Interleukins 
regulate cell growth, differentiation, and motility. They are particularly important in 
stimulating immune response, such as inflammation. ILs (IL-1 to IL-38) function and 
play significant role in various diseases and their expression/production is influenced 
by the polymorphisms and mutations in their encoding genes [69].
5.1 IL-10 gene polymorphism
IL10 gene encodes IL-10 cytokine which suppresses the production of pro-
inflammatory cytokines such as IL-1, IL-6, IL-12, TNF, and interferon gamma 
(IFN-γ), and inhibits the costimulatory activity of macrophages for T cell and NK 
cell activation [70]. IL-10 production may be regulated at the transcriptional level 
and several single nucleotide polymorphisms (SNPs) at the promoter region of 
IL-10 gene have been shown to be associated with changes in the expression levels 
of IL-10 [25, 42].
Numerous recent studies have demonstrated an association between BD and SNPs 
of IL10. Three polymorphisms -1082 A/G (rs1800896), -819 T/C (rs1800871) and 
-592 A/C (rs1800872) in the promoter region of the IL-10 gene are correlated to the 
expression level of IL-10. There are inconsistent reports on the association of IL-10-
1082 A/G, -819 T/C and -592 A/C polymorphisms and BD (Tables 8–10). Two recent 
studies suggested significant association of genotype GG of IL-10-1082 A/G with BD 
susceptibility in Saudis [14] and Egyptian [71]. Earlier Wallace et al. [72] showed weak 
association of genotype AA with BD in UK and middle-eastern cohort. Moreover 
a meta-analysis also shows that there is a significant association of IL-10-1082 A/G 
polymorphism with BD susceptibility [34]. While there is no significant association of 
this polymorphism in Turkish and Iranian BD patients (Table 8) [28, 45, 53].
Population Case/controls Genotype/allele/polymorphism Association Reference
Saudi 61/200 GG Susceptible [14]
Egyptian 87/97 GG Susceptible [71]
UK+ME 178/295 AA Weekly 
associated
[72]
Turkish 97/127 GA polymorphism No association [53]
Turkish 102/102 GA polymorphism No association [45]
Iranian 150/140 GA polymorphism No association [28]
Meta-analysis 199/229 GG+GA Susceptible [34]
Table 8. 
Association of IL-10-1082 polymorphism with BD susceptibility.
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IL-10-819 T/C polymorphism has been studied in different populations 
(Table 9). Reports indicate that IL-10-819 T/C polymorphism is associated with 
susceptibility of BD in Algerians [73], British [72], Chinese [74, 75] and Saudi 
patients [14]. While it is not significantly associated with BD in Turkish [11, 45, 
53], Iranian [28], Japanese and Korean patients [11]. However two independent 
meta-analysis showed that IL-10-819 T/C polymorphism is associated with BD 
[11, 34]. In a meta-analysis containing of 2472 cases and 2820 controls, Liang 
et al. [34] suggested that IL-10-819 T/C polymorphism is associated with BD 
susceptibility.
Population Case/controls Genotype/allele/polymorphism Association Reference
Saudi 61/200 TT Susceptible [14]
Chinese 407/679 CT polymorphism Susceptible [74]
Chinese Han 718/1753 T-allele Susceptible [75]
Algerian 51/96 T-allele Susceptible [73]
British 178/295 T-allele Susceptible [72]
Turkish 102/102 CT polymorphism No association [45]
Turkish 97/127 CT polymorphism No association [53]
Turkish 1215/1279 CT polymorphism No association [11]
Japanese 611/737 CT polymorphism No association [11]
Korean 119/140 CT polymorphism No association [11]
Iranian 150/140 CT polymorphism No association [28]
Overall mixed 1945/2156 CT polymorphism Susceptible [11]
Meta-analysis 2472/2820 CT polymorphism Susceptible [34]
Table 9. 
Association of IL-10-819 polymorphism with BD susceptibility.
Population Case/controls Genotype/allele/polymorphism Association Reference
Saudi 61/200 AA Susceptible [14]
Algerian 51/96 A-allele Susceptible [73]
Iranian 150/140 CA polymorphism No association [28]
Iranian (Azeri 
Turkish)
47/58 A-Allele Susceptible [76]
Chinese Han 718/1753 A-Allele Susceptible [75]
Spanish 304/313 A-Allele Susceptible [77]
Turkish 102/102 CA polymorphism No association [45]
Turkish 97/127 CA polymorphism No association [53]
Turkish 1215/1279 CA polymorphism No association [11]
Japanese 611/737 CA polymorphism No association [11]
Korean 119/140 CA polymorphism No association [11]
Overall mixed 1945/2156 CA polymorphism Susceptible [11]
Meta-analysis 2294/2525 CA polymorphism Susceptible [34]
Table 10. 
Association of IL-10-592 polymorphism with BD susceptibility.
Cytokines
10
Available literature shows that 11 studies focused on relationship of IL-10-592 
A/C polymorphism and BD risk (Table 10). A significant association of this poly-
morphism has been reported in five studies from different ethnicity namely Algerian 
[73], Iranian (Azeri Turkish) [76], Chinese Han [75], Saudi [14] and Spanish BD 
patients [77]. In our study with Saudi patients we found that −592 AA genotypes of 
IL-10 is significantly associated with susceptibility risk of BD in Saudi patients [14].
On the other hand three studies on Turkish [11, 45, 53], one each on Iranian 
[28], Japanese and Korean BD patients [11] show no significant association of this 
polymorphism with BD susceptibility. A meta-analysis containing 2294 patients 
and 2525 controls suggested that IL-10-592 A/C polymorphism is associated with 
BD susceptibility [34].
Two independent GWA studies of Turkish and Japanese populations show that 
IL-10 is among the first two BD susceptibility loci outside the MHC with genome-
wide significance [11, 16]. Intronic polymorphism (rs1518111) is associated with 
BD susceptibility in the Turkish population [16] while promoter polymorphisms in 
IL-10 gene (rs1800871 and rs1800872) are associated with BD in Japanese [11]. The 
variant rs1518111 has been replicated in BD patients of British, Greek, Korean and 
Middle Eastern ethnicity and rs1800872 replicated in Turkish and Korean samples 
[11, 16]. Recently Wu et al. [74] reported the replication of rs1518111 and rs1800871 
variants in BD patients from Han Chinese population. The SNP rs1518111 has also 
been replicated in in the Iranian population showing association with BD [78]. The 
data from HapMap Project indicate that these three polymorphisms are in strong 
linkage disequilibrium in populations from both European and Asian ancestries. The 
decrease in risk allele A of rs1518111 is associated with decreased IL10 expression in 
monocytes by 35% compared with the non-risk allele G in Turkish patients with BD.
The homozygous genotype AA of rs1518111 is associated with decrease in IL-10 
protein in monocytes and found to be stimulated with Toll-like-receptor ligands, 
such as lipopolysaccharide or the lipoprotein Pam3Cys and muramyl dipeptide [16]. 
Talat et al. [71] reported that IL-10 serum levels are lower in BD patients than in 
controls. Baris et al. [79] suggested that IL-10 polymorphisms can be statistically 
associated with the disease symptoms and used as prognostic factors.
5.2 IL-1 gene polymorphism
Several cytokine genes may play crucial roles in host susceptibility to Behçet's 
disease (BD), since the cytokine production capacity varies among individuals 
and depends on the cytokine gene polymorphisms. Interleukin-1 (IL-1) and the 
IL-1 receptor (IL-1R) family plays an important role in the pathogenesis of inflam-
matory diseases. The association of the IL-1 cluster gene polymorphisms with the 
development of BD has been investigated in several studies.
5.2.1 IL-1α −889C/T polymorphism
Six reports are available on IL-1α -889C/T polymorphism and Behçet’s disease 
(Table 11). Out these five studies were performed on Turkish patients [55, 58, 80–82] 
while one on Iranian BD patients [48]. There was no association of this gene polymor-
phism and the susceptibility of BD except one study which showed CC genotype to be 
associated with BD susceptibility in Turkish patients [55].
5.2.2 IL-1β −511C/T polymorphism
Four studies are found which focused to assess the importance of IL-1β −511C/T 
polymorphism for BD susceptibility (Table 11). The comparisons of allele and 
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genotype failed to detect any statistical association under the random effect model 
in three studies [58, 80, 82] however one study reported that CC genotype of IL-1β 
−511C/T polymorphism is associated with BD susceptibility in Turkish patients [55].
5.2.3 IL-1β −3962 C/A polymorphism
Some workers have studied IL-1 β −3962 C/A polymorphism and assessed the 
effect of the IL-1β −3962C/A polymorphism in the occurrence of BD in Turkish and 
Iranian patients (Table 11). They did not find any significant association between 
IL-1β −3962 C/A polymorphism with BD between allele and genotype frequencies 
in Turkish and Iranian BD patients [48, 58, 82] however one study indicates associa-
tion of IL-1 β −3962 C/A polymorphism with BD in Turkish patients [55].
Ozçimen et al. [82] studied IL-1 cluster gene polymorphisms in Turkish patients 
with Behçet's disease and suggested that polymorphisms in IL-1β gene may affect 
host susceptibility to BD. The IL-1β production in the active period has been found 
to be greater than in the remission period of BD. IL-1β production is considered to 
be related to posterior segment type attacks of Behçet's disease [83].
Baris et al. [79] observed no significant differences between the groups with 
respect to the IL-1Ra, IL-1β, IL-2, IL-6 and the IL-10 gene polymorphism distribu-
tions and suggested that the IL-1RN2 gene polymorphism is correlated with the 
presence of articular involvement and the IL-1β gene polymorphism with the 
presence of an ocular lesion. On the basis of the correlations between the articular 
involvement and IL-1RN, the ocular involvement and the IL-1β, gene polymor-
phisms, it has been suggested that these polymorphisms could be statistically 
associated with the disease symptoms and may be used as prognostic factors [79].
6. Interleukin (IL)-6
IL-6 pleitropic cytokine is involved in immune and inflammatory responses. 
Various polymorphisms in IL-6 gene have been associated with chronic inflammatory 
Population Case/controls Polymorphism Association Reference
Turkish 132/106 IL-1α-889C/T No association [80]
Turkish 72/163 IL-1α-889C/T No association [81]
Turkish 80/105 IL-1α-889C/T CC associated [55]
Turkish 57/57 IL-1α-889C/T No association [58]
Turkish 97/77 IL-1α-889C/T No association [82]
Iranian 150/140 IL-1α-889C/T No association [48]
Turkish 132/106 IL-1β-511C/T No association [80]
Turkish 80/105 IL-1β-511C/T CC associated [55]
Turkish 57/57 IL-1β-511C/T No association [58]
Turkish 97/77 IL-1β-511C/T No association [82]
Turkish 57/57 IL-1β-3962C/T No association [58]
Turkish 80/105 IL-1β-3962C/T CC associated [55]
Turkish 97/77 IL-1β-3962C/T No association [82]
Iranian 150/140 IL-1β-3962C/T No association [48]
Table 11. 
Association of IL-1 polymorphisms with BD susceptibility.
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and autoimmune disorders [84–88]. Higher levels of IL-6 and increased expression of 
IL-6 mRNA have been reported in subjects with active BD [20, 89, 90]. A few studies 
have focused on the polymorphism of IL-6 −174 G/C in BD patients (Table 12). The 
polymorphism of IL6 −174 G/C does not modulate clinical expression of BD. The 
single nucleotide polymorphism of the IL-6 does not appear to be associated with 
BD susceptibility in Egyptian [71], Korean [90], Tunisian [20], Turkish and German 
patients [53, 56]. The GG genotype of IL-6 −174 G/C polymorphism is protective in 
Iranian population [48]. It is believed that the scarcity of studies of polymorphism 
of IL-6 in BD is related to the fact that IL-6 is a pro-inflammatory cytokine of Th2, 
whereas BD is a Th1 disease. Recently a meta-analysis suggested that IL-6-174 G/C 
polymorphism decreases the risk of BD [91].
7. IL23R-IL12RB2 polymorphisms
The IL23R–IL12RB2 polymorphisms in Behçet’s disease have been subject of 
several studies in various ethnic populations (Table 13). The IL23R–IL12RB2 locus 
is one of the few loci with genome-wide significance. The SNP rs1495965, located in 
the intergenic region between IL23R and IL12RB2 is associated with BD in Japanese 
[11]. Another polymorphism (rs924080) in the intergenic region between IL23R 
and IL12RB2 has been associated with BD in Turkish patients [16]. However, these 
association are not replicated in Korean, Middle Eastern Arab, Greek, and British 
subjects possibly due to small sample size [16].
The rs924080 has been replicated in the Iranian population and major allele is 
associated with BD [78]. Other polymorphisms rs7539328, rs12119179, rs1495965 
have also been associated with BD susceptibility in Iranian patients [92]. Moreover 
minor allele of IL23R polymorphisms, Arg381Gln in the Turkish population and 
Gly149Arg in the Japanese population are associated with protection from BD as 
these variants reduce its ability to respond to IL-23 stimulation [99]. Disease–asso-
ciated, intergenic non-coding variants (major alleles) are associated with increased 
expression of IL23R compared with the disease-protective minor alleles [99].
The IL-23 receptor is expressed on the surface of Th17 cells and macrophages. 
It is encoded by IL23R gene. IL-23 is composed of p19 and p40 subunits which is 
shared with IL-12. IL-23, being a proinflammatory cytokine promotes Th17 cell 
Population Case/controls Genotype/allele/polymorphism Association Reference
Tunisian 43/43 G/C polymorphism No 
association
[20]
Egyptian 87/97 G/C polymorphism No 
association
[71]
Iranian 150/140 GG Protective [48]
Turkish/German 121/70 G/C polymorphism No 
association
[56]
Turkish 97/127 G/C polymorphism No 
association
[53]
Korean 89/123 G/C polymorphism No 
association
[90]
Meta-analysis 2065/1159 G/C polymorphism Decrease the 
risk
[91]
Table 12. 
Association of IL-6 (174G/C) polymorphism with BD susceptibility.
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development and induces the production of IL-1, IL-6, IL-17 and TNF [100]. Th17 
cells by producing IL-17 play a significant role in inflammation and autoimmune 
diseases. Steinman [101] suggested that the disease-associated alleles increase IL-23 
receptor expression or signaling compared with the disease-protective alleles. Thus 
it is evident that the disease-associated variants increase the BD susceptibility by 
influencing IL23R, however an alternative or additional role to influence expression 
of the other nearby gene, like IL12RB2, cannot be excluded. IL-12 receptor beta2, 
a subunit of IL-12 receptor is encoded by IL12RB2 gene. IL12RB2 is responsible for 
high-affinity IL-12 binding and IL-12 dependent signaling, and plays an important 
role in Th1 cell differentiation. IL-12 has been suggested to be involved in Th1 
responses, T cell and NK cell cytotoxicity, and IFN-γ production by T cells and NK 
cells [102]. As there is no data available on quantitative trait loci for these non-
coding variants influencing IL12RB2 or IL23R expression, there is a possibility that 
their effects are expressed only in a specific cell type or under certain conditions as 
suggested by Takeuchi et al [15].
Yu et al. [95] performed genome wide association study on 1206 patients with 
BD and 2475 healthy controls and confirmed the association of IL-10 819 C/T and 
IL23R IL12RB2/rs924080 with BD. They (loc. cit.) also identified two susceptibil-
ity single nucleotide polymorphisms in IL10 and IL23R-IL12RB2 (rs3024490 and 
rs12141431) with BD in Han Chinese.
8. IL12A polymorphisms
IL12A encodes IL-12p35, a subunit of the heterodimer of IL-12, is known to 
play a critical role in polarization of the Th1 pathway through differentiation from 
Population Case/controls Polymorphism Association Reference
Iranian 973/637 rs10489629
rs1343151
rs1495965
Susceptible [78]
Iranian 552/417 rs7539328,
rs12119179,
rs1495965,
Susceptible [92]
Korean 369/2000 rs1495965
rs1495966
rs4655535
Susceptible [93]
Chinese Han 407/421 rs924080
rs11209032
Susceptible [94]
Chinese Han 1206/2475 rs3024490
rs12141431
Susceptible [95]
Chinese Han 806/1600 rs3212227 Susceptible [96]
Chinese Han 27/32 rs17375018 Susceptible [97]
Algerian 51/96 rs12119179
rs11209032
rs924080
decrease risk [73]
Egyptian rs17375018 Susceptible [13]
Turkish 123/168 rs17375018 Susceptible [98]
Japanese 612/740 rs1495965 Susceptible [11]
Turkish 2430/2660 rs924080 Susceptible [16]
Table 13. 
Association of IL23R-IL12RB2 polymorphisms with BD susceptibility.
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naïve CD4+ T cells. A variant rs1780546, located in the intergenic region near IL12A 
has been associated with BD in a Turkish cohort however the association did not 
achieve genome-wide significance as it is not polymorphic in the Japanese cohort 
[99]. Recently, Kappen et al. [103] reported an association of rs1780546 with BD 
susceptibility and showed genome-wide association after meta-analysis with 
previous Turkish GWAS data. This GWAS was based on 336 cases and 5843 controls 
in cohorts of mixed ethnicity using linear mixed models to correct for ancestry 
differences and family structure and/or cryptic relationships. However no report is 
available on functional aspect of rs1780546 [102].
9. IL-33 gene polymorphism
Members of the IL-1 family play a pivotal role in the inflammatory responses 
[104]. IL-33 belongs to IL-1 superfamily. Some studies have implicated the 
IL-33 ligand for the ST2 receptor in the pathogenesis of BD [105–107]. IL-33 is 
encoded by IL-33 gene and expressed in epithelial, endothelial, inflammatory 
and central nervous system cells. IL-33 can function both as a cytokine and as 
a nuclear factor regulating gene transcription due to the fact that its expres-
sion increases in pro-inflammatory conditions. Cells of the affected area play a 
significant role in the pathogenesis of BD by recruiting, activating and promot-
ing survival of inflammatory cells. Therefore the use of immunosuppressant like 
azathioprine, cyclosporine, corticosteroids or anti-TNF-α monoclonal antibod-
ies (mAb) which interferes the cytokine network is the basis of BD treatment 
strategies [6, 20, 108].
The TT variants of rs7044343 and rs11792633 polymorphisms in IL-33 gene 
are very rare, and the T allele frequencies of these polymorphisms has been 
reported to be lower in the BD group compared to the controls. The rs7044343 
and rs11792633 variants of IL-33 gene are associated with the decreased risk of 
BD in Turkish cohort. It has been suggested that IL-33 acts a protective role on the 
pathogenesis of BD [109].
10. Interferon-γ (IFN-γ)
IFN-γ is antiviral, antitumor and immunomodulatory cytokine. It has a critical 
role in modulating the IL-4, IL-10 and IL-12 cytokine network pathway. It is also 
considered as a pro-inflammatory cytokine because of its effects on TNF activity. It 
has been reported that the frequencies of IFN-γ +874A allele and A/A genotype are 
higher in BD patients than in healthy controls, and individuals with this genotype 
are more susceptible to the disease [55]. However later studies on Turkish and 
Iranian patients failed to find any significant association of IFN-γ +874 A/T poly-
morphism with BD susceptibility (Table 14) [28, 53].
Population Case/controls Genotype/allele/polymorphism Association Reference
Turkish 80/105 AA/A Susceptible [55]
Turkish 97/127 A/T polymorphism No association [53]
Iranian 150/140 A/T polymorphism No association [28]
Table 14. 
Association of IFN-γ (+874A/T) polymorphism with BD susceptibility.
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11. Transforming growth factor-β1 gene polymorphism
Transforming growth factor-β1 (TGF-β1) is an effective immunosuppressive 
cytokine. It is produced in response to tissue injury by activated macrophages. TGF-
β1 is responsible for inhibition of macrophage activation and modulation of T cell 
function [110, 111]. It is also involved in tissue fibrosis by increasing the synthesis 
of extracellular matrix components [112]. The frequency of TGF-β1 codon 10–25 
T/C-G/C genotype in Turkish BD patients has been reported to be higher than those 
of healthy controls [53] while GG genotype has been reported to be susceptible to 
BD in Iranian cohort (Table 15) [28].
Recent studies have focused on the functional relevance of the various genes 
associated with susceptibility of BD and possible interaction between the genes 
located within and outside the MHC region [14, 24, 113, 114]. The functional 
relevance of allele A and genotype GA of TNF-α (308G/A) and association with BD 
has been indicated in various studies [24, 114]. The increased frequency of allele-A 
in BD patients is linked with higher levels of TNF-α reported in active BD patients 
as compared to controls [24, 114].
The pro-inflammatory cytokines induce inflammation and the severity of the 
inflammatory responses is influenced by the levels of cytokines. The activated mac-
rophages produce higher levels of cytokines affecting not only the severity of the 
local inflammatory responses but also exert systemic effects. The over-expression of 
these cytokines is considered to be responsible for the pathogenesis of recurrent BD 
[33]. TNF-α, a pro-inflammatory cytokine has been suggested to be responsible for 
the pathogenesis of BD by activating T-cells and neutrophils [115].
On the other hand increased frequency of low producer 1082GG genotype of IL-10 
(an anti-inflammatory cytokine) in BD patients may not suppress the TNF-α- activ-
ity and resulting inflammatory responses, as IL-10 is known to limit the secretion of 
pro-inflammatory cytokines, such as TNF-α and IL-12 [70]. Moreover the deficiency of 
IL-10 and resulting prolonged activation of mononuclear cells may lead to an augmented 
efflux of inflammatory cytokines and further aggravate the severity of BD as IL-10 is a 
multi-functional cytokine with role in diverse areas of the human immune system [116].
The information regarding the association of various gene polymorphisms will 
have prognostic value for future clinical observations. Especially the data of TNF-α 
(−308) polymorphism will provide guideline in anti-TNF-α therapy as patients with 
GG genotype are better responders to anti-TNF-α treatment than those with AA 
or GA [117, 118]. However, such genetic associations with BD susceptibility need 
further validation and investigation in more patients with BD from various ethnic 
populations, as they may have implications for the development of novel therapies 
as suggested by Xavier et al [78].
12. Conclusion
In spite of recent advances in genetics and immunology leading to a better under-
standing of the immunopathogenesis, the etiology of BD is still unclear. Various 
Population Case/controls Genotype/allele Association Reference
Turkish 97/127 T/C-G/C Susceptible [53]
Iranian 150/140 CC Susceptible [28]
Table 15. 
Association of TGF-β1 (509 C/T) polymorphism with BD susceptibility.
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genetic, immunological and micro- and macro-environmental factors are believed 
to be involved in the development of BD. The HLA-B∗51 allele and variants in IL-10, 
TNF-α, TGF-β and at the IL-23–IL-12RB2 loci are the genetic factors most closely 
associated with BD. The variations in the association between various polymorphisms 
discussed and BD in different ethnicity/populations may reflect the heterogeneity in 
the genetic susceptibility to this disorder. Since the clear pathogenesis of BD remains 
to be elucidated, it is highly suggestive that multiple host genetic factors are involved 
in the development of BD. Therefore, further genetic studies on BD patients of 
different ethnicity and genes associated with immunity are expected to elucidate BD 
pathogenesis and also to contribute to the development of more targeted therapies 
and biomarkers.
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